drugset
drugset / Trial / NCT03245736

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

NCT03245736 ↗

Phase 2 Completed 5 enrolled Seagen Inc. Genmab · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.

Timeline

Start
2017-08-23
Primary completion
2019-01-10
Completion
2019-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tisotumab Vedotin Other / unclassified — —

Indications

cervical cancer endometrial cancer esophageal cancer head and neck squamous cell carcinoma non-small cell lung carcinoma ovarian cancer prostate cancer urinary bladder cancer